Suven Life Sciences, a biopharmaceutical company specialising in drug discovery and developmental activities in central nervous system disorders, announced its un-audited financial results for the quarter ended September 30, 2012. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting at Hyderabad.
The second quarter ended September 2012, the company has reported a growth in revenue of Rs 503 million, growth in PAT of Rs 64 million, and growth in EBIDTA of Rs 110 million.
The financial highlights for the half year-ended September 2012 has reported a growth in revenue Rs 1208 million, growth in PAT of Rs 145 million and growth in EBIDTA of Rs 249 million.
Suven’s major thrust on innovative R&D in drug discovery continues with a spending of Rs 156 million (13 per cent on revenue) for the half year ended September 2012.
During the quarter the major qualitative achievement include Suven getting Pharmexcil’s ‘Platinum Patent Award’ for securing the most number of product and process patents under overall category, fourth year in a row. Suven has a patent profile of 18 inventions, 541 product patents and 36 process patents. The product profile has 13 molecules with one molecule having completed phase 1 study, is in the process of moving into phase 2a, proof of concept study.
EP News Bureau